Quality Control

Understanding Peptide Purity: HPLC, Mass Spec, and Why ≥99% Matters

A primer on how research-grade peptide purity is measured — what HPLC and mass spectrometry actually tell you, what the impurities in a 95% vs 99% peptide are, and how to read a certificate of analysis to evaluate the material going into your research. April 18, 2026Quality Control13 min read

Why Purity Is the Most Important Specification

When evaluating a research peptide, purity is the single most important quality indicator — more than price, brand, or even source country. A peptide's biological activity, dose-response relationship, and research reproducibility are directly proportional to its purity. A nominally "identical" peptide at 95% purity vs 99% purity is not simply 4% less effective — the 5% impurity fraction may contain synthesis byproducts with antagonistic activity, deleted-sequence fragments that compete for the target receptor, or reactive species that degrade the active compound or confound assays.

Understanding what purity numbers actually mean — and what analytical methods produce them — allows researchers to critically evaluate supplier certificates of analysis and select material appropriate for their specific research context.

Purity Grade Tiers

>95% Standard

Minimum acceptable for most biochemical assays. 5% impurity fraction present. Not recommended for in vivo models or receptor binding studies.

>98% Research Grade

Suitable for most cell-based and animal research. Impurity burden reduced. Acceptable for published research with appropriate COA documentation.

≥99% High Purity

Standard for rigorous preclinical research. Impurity fraction below 1%. Required for dose-response studies and receptor pharmacology research.

>99.5% Pharmaceutical

Pharmaceutical manufacturing standard. Required for IND-enabling studies and clinical trial material. Involves additional characterisation beyond HPLC/MS.

HPLC: What It Measures and How

Reverse-phase high-performance liquid chromatography (RP-HPLC) is the gold standard method for peptide purity determination. In RP-HPLC, the reconstituted peptide sample is injected into a column packed with hydrophobic stationary phase (typically C18-bonded silica). A gradient of organic solvent (usually acetonitrile with 0.1% trifluoroacetic acid) is applied, causing different components in the sample to elute at different times based on their hydrophobicity. Peptide components absorbing UV light at 214–220 nm (peptide bond absorption) or 280 nm (aromatic residue absorption) are detected as they exit the column.

The output is a chromatogram — a plot of UV absorbance vs time. The target peptide elutes as the dominant peak; impurities appear as smaller peaks flanking it or baseline noise. Purity percentage is calculated from the area under the target peak relative to the total integrated area of all detected peaks:

Purity (%) = (Area of target peak ÷ Sum of all peak areas) × 100

This is an important limitation to understand: HPLC purity is a relative, not absolute, measurement. It measures the proportion of UV-absorbing material represented by the target compound — but does not quantify non-UV-absorbing species (salts, solvents, water, some small molecule contaminants) that may also be present. A 99% HPLC purity does not mean the sample is 99% peptide by mass — it means 99% of the UV-absorbing species are the target compound.

What HPLC Does Not Detect

HPLC purity measurement has known blind spots. It does not detect: residual solvents (TFA, acetonitrile, DMF from synthesis) below UV absorbance thresholds; inorganic salts (counter-ions from purification, typically acetate or TFA); water content (most lyophilized peptides are 5–15% water by mass, which is not reflected in HPLC purity); and endotoxin (lipopolysaccharide from bacterial contamination, relevant for in vivo research). A comprehensive quality profile requires additional tests beyond HPLC — which is why a full certificate of analysis includes multiple assay types.

Mass Spectrometry: Confirming Identity

Mass spectrometry (MS) is the complementary analytical tool to HPLC: while HPLC tells you how much of the target compound is present relative to impurities, MS tells you whether the compound present is actually the correct peptide. MS determines molecular mass by measuring the mass-to-charge ratio (m/z) of ionized species in the sample.

For research peptides, electrospray ionization mass spectrometry (ESI-MS) is standard. The peptide solution is sprayed through a charged needle, producing multiply-charged ions that are separated and measured by the mass analyser. The resulting spectrum shows characteristic peaks at m/z values corresponding to the peptide's molecular weight divided by its charge states (typically [M+2H]²⁺, [M+3H]³⁺, and so on for larger peptides). The measured molecular weight is compared against the theoretical molecular weight calculated from the amino acid sequence.

Why Both Tests Are Required

HPLC without MS can confirm purity but not identity — a highly purified impurity would show a clean HPLC trace while not being the target compound at all. MS without HPLC can confirm identity but not purity — a low-purity sample containing the correct peptide plus impurities would show the correct molecular weight. Both tests together confirm that the dominant compound in the sample is the correct peptide at the stated purity level. A reputable supplier's COA should always include both.

Common Impurities in Synthetic Peptides

Impurity TypeOriginDetected ByResearch Impact Deletion sequencesFailed coupling during solid-phase synthesis — one or more amino acids missing from the sequenceHPLC (slightly different retention time), MS (lower MW)High — deletion peptides may act as partial agonists or antagonists at the same receptor Oxidised variantsOxidation of methionine, cysteine, or tryptophan residues during synthesis, purification, or storageHPLC (shifted peak), MS (+16 Da per oxidation)Moderate — oxidised residues alter receptor binding and may reduce potency Deamidated variantsDeamidation of asparagine or glutamine during synthesis or storageHPLC, MS (+1 Da)Low–moderate — subtle structural change that may affect binding at sensitive sites TFA counter-ionTrifluoroacetic acid used in RP-HPLC purification remains as a counter-ion unless specifically removedIon chromatography, NMR (not detected by HPLC/MS)Low for most research; relevant for in vivo as TFA has biological activity at higher doses Racemised amino acidsL→D isomerisation at Cα during harsh synthesis conditions, particularly at Cys and His residuesChiral HPLC, amino acid analysis (not standard MS)Variable — D-amino acid incorporation at key positions can significantly alter biological activity AggregatesIntermolecular associations forming oligomers or larger aggregates, especially in storageSize exclusion chromatography (SEC), DLS (not standard HPLC)High — aggregated peptide has reduced or altered receptor activity and increased immunogenicity potential Endotoxin (LPS)Bacterial contamination during synthesis or processing — lipopolysaccharide from gram-negative bacteriaLimulus Amebocyte Lysate (LAL) assay — not detected by HPLC or MSVery high for in vivo research — endotoxin causes potent inflammatory response that confounds any biological endpoint

Reading a Certificate of Analysis

A certificate of analysis (COA) is the quality documentation accompanying each research peptide lot. Understanding what a comprehensive COA should contain — and what red flags look like — is essential for critical evaluation of research material. A complete COA for a research-grade peptide should include:

Example Certificate of Analysis — Research Peptide (Illustrative) Compound NameIpamorelin acetate SequenceAib-His-D-2-Nal-D-Phe-Lys-NH₂ Molecular FormulaC₃₈H₄₉N₉O₅ · xC₂H₄O₂ Theoretical MW711.86 Da (free base) Measured MW (ESI-MS)712.0 Da [M+H]⁺ ✓ PASS HPLC Purity (RP-C18, 214 nm)99.3% ✓ PASS Water Content (Karl Fischer)7.2% TFA Content<0.1% (ion exchange) AppearanceWhite lyophilized powder Lot NumberIPA-2026-0312-A Analysis DateMarch 12, 2026

Red Flags on a COA

COA red flags that warrant skepticism: HPLC purity listed without a specified detection wavelength or column type (not independently reproducible); MS data showing a molecular weight discrepancy greater than 1 Da from theoretical (suggesting incorrect sequence or significant modification); HPLC purity listed as "≥98%" without the actual measured value (a real COA reports the actual number); analysis date absent or implausibly old (COAs should accompany the specific lot); no lot number linking the COA to a specific production batch; and HPLC chromatogram image unavailable upon request (reputable suppliers provide raw chromatogram data).

Why ≥99% Purity Matters for Research Reproducibility

Beyond the biological impact of specific impurities, purity directly affects dose calculation accuracy. When a peptide is stated as 5 mg but is only 95% pure, the actual active compound mass is 4.75 mg — a 5% dosing error that would be invisible without purity-adjusted dose calculations. For dose-response studies, this systematic error across a dilution series produces shifted curves that misrepresent potency. In reproducibility terms, if two researchers use the same peptide at different purity grades (95% vs 99%), their results will diverge in ways that appear as laboratory-to-laboratory variability but are actually quality-driven artefacts.

Research-grade ≥99% purity is not a marketing distinction — it is a methodological prerequisite for results that can be meaningfully compared across experiments, laboratories, and time points.

Research Use Only — Disclaimer This document is prepared for laboratory and research reference purposes only. Quality control information pertains to research-grade materials for in vitro and preclinical research contexts. This content does not constitute medical advice. Pharmaceutical-grade quality requirements for human use involve additional regulatory and analytical standards beyond those described here. Researchers must comply with all applicable institutional and regulatory requirements.

References

1. Merrifield RB. "Solid phase peptide synthesis." J Am Chem Soc. 1963;85(14):2149–2154.
2. Bouvier ESP, Iraneta PC. "Reversed-phase HPLC: the basics." Waters Corporation Application Note. 2012.
3. Ingle JD, Crouch SR. Spectrochemical Analysis. Englewood Cliffs: Prentice-Hall; 1988.
4. ICH Q1A(R2). "Stability Testing of New Drug Substances and Drug Products." International Council for Harmonisation. 2003.
5. Manning MC, et al. "Stability of protein pharmaceuticals: an update." Pharm Res. 2010;27(4):544–575.
6. Kaspar AA, Reichert JM. "Future directions for peptide therapeutics development." Drug Discov Today. 2013;18(17–18):807–817.